410 related articles for article (PubMed ID: 30940536)
41. Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease.
Pietropaolo S; Bellocchio L; Ruiz-Calvo A; Cabanas M; Du Z; Guzmán M; Garret M; Cho YH
Neuropharmacology; 2015 Feb; 89():368-74. PubMed ID: 25123645
[TBL] [Abstract][Full Text] [Related]
42. In vivo evaluation of the CB
Mustafa M; Donvito G; Moncayo L; Swafford A; Poklis J; Grauer R; Olszewska T; Ignatowska-Jankowska B; Kendall DA; Lu D; Lichtman AH
Pharmacol Biochem Behav; 2020 Mar; 190():172840. PubMed ID: 31899221
[TBL] [Abstract][Full Text] [Related]
43. Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.
Herbst EA; Holloway GP
Neuroscience; 2015 Sep; 303():515-23. PubMed ID: 26186895
[TBL] [Abstract][Full Text] [Related]
44. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
[TBL] [Abstract][Full Text] [Related]
45. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.
Denovan-Wright EM; Robertson HA
Neuroscience; 2000; 98(4):705-13. PubMed ID: 10891614
[TBL] [Abstract][Full Text] [Related]
46. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse.
Naver B; Stub C; Møller M; Fenger K; Hansen AK; Hasholt L; Sørensen SA
Neuroscience; 2003; 122(4):1049-57. PubMed ID: 14643771
[TBL] [Abstract][Full Text] [Related]
47. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
48. Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility.
Schaffer PC; Kulkarni PM; Janero DR; Thakur GA
Bioorg Med Chem; 2020 Nov; 28(21):115727. PubMed ID: 33065437
[TBL] [Abstract][Full Text] [Related]
49. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
Dufour BD; McBride JL
Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
[TBL] [Abstract][Full Text] [Related]
50. Allosteric modulators restore orthosteric agonist binding to mutated CB
Dopart R; Kendall DA
J Pharm Pharmacol; 2020 Jan; 72(1):84-91. PubMed ID: 31722122
[TBL] [Abstract][Full Text] [Related]
51. The absence of the aryl hydrocarbon receptor in the R6/1 transgenic mouse model of Huntington's disease improves the neurological phenotype.
Angeles-López QD; García-Lara L; Aguirre-Pineda N; Castañeda-Arellano R; Elizondo-Azuela G; Pérez-Severiano F; Segovia J
Behav Brain Res; 2021 Jun; 408():113230. PubMed ID: 33684424
[TBL] [Abstract][Full Text] [Related]
52. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.
Gado F; Meini S; Bertini S; Digiacomo M; Macchia M; Manera C
Future Med Chem; 2019 Aug; 11(15):2019-2037. PubMed ID: 31517528
[TBL] [Abstract][Full Text] [Related]
53. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
[TBL] [Abstract][Full Text] [Related]
54. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
[TBL] [Abstract][Full Text] [Related]
55. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
56. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
Lastres-Becker I; Fezza F; Cebeira M; Bisogno T; Ramos JA; Milone A; Fernández-Ruiz J; Di Marzo V
Neuroreport; 2001 Jul; 12(10):2125-9. PubMed ID: 11447320
[TBL] [Abstract][Full Text] [Related]
57. Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease.
Laprairie RB; Kelly ME; Denovan-Wright EM
Neuropharmacology; 2013 Sep; 72():47-57. PubMed ID: 23602984
[TBL] [Abstract][Full Text] [Related]
58. Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin-induced neuropathic pain in mice.
Bagher AM; Binmahfouz LS; Shaik RA; Eid BG
Saudi Pharm J; 2023 Feb; 31(2):255-264. PubMed ID: 36942271
[TBL] [Abstract][Full Text] [Related]
59. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
60. Determination of the Cannabinoid CB1 Receptor's Positive Allosteric Modulator Binding Site through Mutagenesis Studies.
Green HM; Fellner DMJ; Finlay DB; Furkert DP; Glass M
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
